Approval Year
| Substance Class |
Structurally Diverse
Created
by
admin
on
Edited
Sun Dec 18 17:16:05 UTC 2022
by
admin
on
Sun Dec 18 17:16:05 UTC 2022
|
| Source Materials Class | ORGANISM |
| Source Materials Type | VIRUS |
| Source Materials State | LIVE |
| Organism Family | Coronaviridae |
| Organism Genus | Betacoronavirus |
| Organism Species | severe acute respiratory syndrome-related coronavirus |
| Author | NONE |
| Infraspecific Type | STRAIN |
| Infraspecific Name | SARS-CoV-2 |
| Part | WHOLE |
| Record UNII |
B6L4N5Z4GH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
B6L4N5Z4GH
Created by
admin on Sun Dec 18 17:16:07 UTC 2022 , Edited by admin on Sun Dec 18 17:16:07 UTC 2022
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
On February 5, 2021 Sinovac announced data from a 12,396-participant, Phase III trial in Brazil and Turkey showing CoronaVac to be 100% effective in preventing death or hospitalization in patients with COVID-19, 83.7% effective in avoiding cases that required any medical treatment, but just 50.65% effective at preventing infection with the virus.
EFFICACY
|
||
|
|
VACCINE ANTIGEN->TARGET |
|
||
|
INHIBITOR->TARGET ORGANISM |
DRUG APPROVED IN CHINA FOR COVID-19. Prodrug that InhibitS the RNA-dependent RNA polymerase after activation to triphosphate.
|
||
|
INHIBITOR->TARGET ORGANISM |
A guanine derivative approved for treating HCV and respiratory syncytial virus (RSV) that has been evaluated in patients with SARS and MERS, but its side effects such as anaemia may be severe at high doses.
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
In Vero E6 cells inhibits. Targets the RNA-dependent RNA polymerase and block viral RNA synthesis in a broad spectrum of RNA viruses, including human coronaviruses. A US patient with 2019-nCoV recovered after receiving intravenous remdesivir in January
BIOASSAY (CELLULAR)
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
IN-VITRO
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
The antibody binds selectively to the spike protein of SARS-CoV-2.
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET |
|
||
|
TARGET ORGANISM->VACCINE ANTIGEN |
AGAINST COVID DISEASE
EFFICACY
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis
EFFICACY
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
In Vero E6 cells
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
nother in vitro study showed that Camostat reduces significantly the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19.[9]
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INFRASPECIFIC -> PARENT ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
Differentiated normal human bronchial epithelial (dNHBE) cells
EC90
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
From 7 days after second dose to a median time of 2 months.
EFFICACY
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
PART/FRACTION -> PARENT ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
after 24 hours incubation; works in cell culture may not work in-vivo
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
Epithelial Vero E6 cells; EC50 Nirmatrelvir = 74.5
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
Has shown antiviral activities in preclinical studies against many RNA viruses, including SARS and MERS.
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
In Vero E6 cells
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
IN-VITRO
|
